1. Home
  2. CATO vs ACET Comparison

CATO vs ACET Comparison

Compare CATO & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cato Corporation (The)

CATO

Cato Corporation (The)

HOLD

Current Price

$3.26

Market Cap

68.5M

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$0.52

Market Cap

93.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CATO
ACET
Founded
1946
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.5M
93.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CATO
ACET
Price
$3.26
$0.52
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
53.9K
1.9M
Earning Date
11-20-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$660,062,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.19
$0.45
52 Week High
$4.92
$1.12

Technical Indicators

Market Signals
Indicator
CATO
ACET
Relative Strength Index (RSI) 42.72 34.97
Support Level $3.35 $0.53
Resistance Level $3.60 $0.57
Average True Range (ATR) 0.17 0.05
MACD 0.02 0.00
Stochastic Oscillator 58.77 20.77

Price Performance

Historical Comparison
CATO
ACET

About CATO Cato Corporation (The)

The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: